Novel therapies , including barzolvolimab and CDX-0159, are demonstrating increasing focus as future options for managing [Disease Area]. Barzolvolimab, an anti- antibody , binds a key process implicated in [Disease Area] pathology. Similarly, CDX-0159, a small compound , presents a unique avenue for reducing patient burden . Early clinical data s